MSHLDostarlimab Vial 500 mg
Monotherapy for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for recurrent or advanced MSI-H or dMMR endometrial cancer.